
第1éš:COVID-19ã®æ¬ºçãè§£ãæãããæ°å'ã³ãããŠã€ã«ã¹
COVID-19ã®ãã³ãããã¯ã¯ãSARS-CoV-2ãŠã€ã«ã¹ããã®äºçš®ã«ãã£ãŠåŒãèµ·ãããããã®ã§ã¯ãªããCOVID-19ã¯æ°çš®ã®Aiçç©å
µåšã§ãããäžéšã¯ãã¯ãããžãŒãäžéšã¯çç©åŠã§ããããããŠããã¯ç¥çã§ããã
ã«ã¬ã³ã»ãã³ã°ã¹ãã³
10æ13æ¥
å èšäºã¯ãã¡ãã
COVID-19ã®ãã³ãããã¯ãåŒãèµ·ãããã®ã¯äžäœäœã ã£ãã®ã ãããïŒ
SARS-CoV-2ãšããæ°åã³ãããŠã€ã«ã¹ãäœçŸäžäººãã®äººã
ãç
æ°ã«ããæ»ã«è³ããããã®ã ãããïŒããã«ïŒnovelïŒãšã¯æ°ãããšããæå³ã ããåæã«é·ãç©èªãã€ãŸãéåžžã«é·ããäœãç©ã®ç©èªãšããæå³ã§ãããã
ã³ãã19ã¹ããŒãªãŒã®å Žåãäºå®ã¯å°èª¬ããå¥ãªããã§ãããæ°åã³ãããŠã€ã«ã¹ãSARS-CoV-2ãCOVID-19ãå€ç°äœãmRNAæè¡ãèŽåœçãªã¹ãã€ã¯èçœãPCRãã¹ãã«ã€ããŠæã ãèããããšã¯ãããŒãã«ã·ãªãŒãºã®æ ç»ã®ããããã«è¿ããã®ã§ãã£ãã
ãã2020幎ã®COVID-19ã®èŠåºããæ£çŽã§æ£ç¢ºã§å®éã«ãã³ãã£ã¯ã·ã§ã³ã§ãããªãã°ã"æªã®æ¯é è ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãšãããšã¢ããŸã«åããçåæAiããå µåšãéœåžãçºã«æ£åžããŠå°çåžæ°ãææã«é¥ãã "ãšèªãã¹ãã ã£ãã®ã§ããã
ãããããæªã®æ¯é è ãã¡ãã¯ãã¹ãã€ã¯ã»ãããã€ã³ãå®éã«ã¯ã人éã«ææããå·ã€ããå®éšããåŠåããããã«äœ¿ãããè質ããç²åïŒLNPïŒæè¡ã«å ãŸããAiç£æ°ãã€ããã²ã«ã§ãããšã¯æ±ºããŠèšããŸããã§ããã
SARS-CoV-2 mRNAãŠã€ã«ã¹ã¯ãmRNAãäœå
ã®çްèã«äŸµå
¥ããåŸãèŽæ»æ§ã®é«ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãçæãããšããæªã®æš©åããã¡ã¯æã
ã«ä¿¡ã蟌ãŸããŠããã®ã§ããã
mRNAã¯äžå®å®ã§ãå£ãããããç¡åïŒäººäœå
ã§ã¯åŒ±ããŠåœ¹ã«ç«ããªãïŒã§ããããšã確èªããç§åŠç蚌æ ãããããããã®ã§ãã
2021幎3æ6æ¥ã®Chemical and Engineering Newsã®èšäºã«ãããšãmRNAã®å®éšå®€ã§ã®å®éšã¯ãmRNAã®çºæãããèªäœã§éåžžã«å£ããããäžå®å®ã§ãããããæŽå²çã«å€±æããŠããŸãããã®C&ENèšäºã«ã¯ã"ç°å¢ãäœå ã®é µçŽ ã¯mRNAãããã«çްããããŠããŸããããå®éšå®€ã§ã®å®éšã¯é£ãããmRNAã现èã«å±ããã®ã¯å€§å€ãªããšã "ãšæžãããŠããŸãããµããã£ã®æé«æè¡è²¬ä»»è å ŒmRNAç ç©¶ã°ããŒãã«è²¬ä»»è ã®ãã©ã³ã¯ã»ãããŒã¶ã¯ãmRNAã«ã€ããŠæ¬¡ã®ããã«è¿°ã¹ãŠããŸãã"æã¯ãïŒmRNAãïŒééã£ãŠèŠãŠããŸããšããã©ãã©ã«ãªã£ãŠããŸããšèšãããŠããŸããã"

ã«ãŒãã®ãŒã¡ãã³å€§åŠã®ååŠã»çç©å·¥åŠéšé·ã§ãããã£ãµãªã³ã»ãã¯ã€ããããå士ã¯ãmRNAã®å®éšãäœå€ã§è¡ãããšããŠããããšã«äžæºã衚æããæ¬¡ã®ããã«è¿°ã¹ãã
ã«ãŒãã®ãŒã¡ãã³å€§åŠã®ãã£ãµãªã³ã»ãã¯ã€ããããå士ã¯ããç§ãã¡ã¯ããïŒmRNAãïŒè©Šéšç®¡å ã§ã¹ã¯ãªãŒãã³ã°ããããšããããŠããŸãããåç©ã®äœå ã§çŽæ¥ïŒmRNAãïŒãã¹ãããæ¹ãæçã ãšæããŸãããšè¿°ã¹ãŠããŸãã

Nature Biotechnologyã2017å¹Žã®æ»èªä»ãè«æãOvercoming Cellular Barriers for RNA Therapeutics in RNAãã«ãããšãmRNAãå«ãRNAéºäŒåæ²»çè¬ã¯ãæ°åå幎ã«ãããé²åã®é²åŸ¡æ©æ§ã§ããè質äºéå±€ã«ãããã©ããªçްèã«ãææããããšãã§ããªãããã§ãã

å é²ã®è質ããç²åïŒLNPïŒæè¡ããªããã°ãmRNAã¯ïŒæ¬æ¥ããã¹ãïŒæ°žé ã®äžæ» ã®ååšã«å¹ãé£ã°ãããŠããã ãããLNPã¯ãmRNAéºäŒåç·šéæè¡ã现èã®è質äºéå±€ã«äŸµå ¥ããææãè€è£œãçåæã¿ã³ãã¯è³ªããã®ä»ã®mRNAé åãæç€ºããçåææ§é ã®çæãå¯èœã«ãããã®ã§ããã

LNPæè¡ã®çŽç²ãªæªã®å€©æã®å€§ãããèšããªãããã®æè¡ãçºæããããŸã§ã¯ã40å幎é²åããè質äºéå±€ã现èããã¹ãŠã®çްèãå®ã£ãŠãããããmRNAã¯äººéã®çްèãå«ããŠãã©ããªçްèã«ãææããããšãã§ããªãã£ãã®ã§ããã
è質ããç²åïŒLNPïŒæè¡ã¯çŽç²ãªæªã§ãããLNPã¯ããã€ãªã¿ã°ãä»ããç¥çµæè¡ãããå µåšãšãèããããŠãããããŸããŸCOVID-19ã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã«ãã£ãããªã®ã§ãã

2018幎ãçŸä»£æŠäºç ç©¶æã§ãžã§ãŒã ãºã»ãžã§ã«ããŒãææãè¡ã£ããŠãšã¹ããã€ã³ãã®è¬çŸ©ã«ããã°ããã®è質ããç²åïŒLNPïŒã¯ãæåãªæå°è ãææ çã»ç²Ÿç¥çã«ä¹ã£åãããå µåšãšããŠäœ¿çšãããŠããããå¿é æ§ã®ãŠã§ã«ããŸãã¯ãè³åäžã®ãã³ãããã¯ããèªçºããããã«äœ¿çšã§ããã®ã ãšããã

ç§ãã¡ãä¿¡ã蟌ãŸãããããäžã€ã®æ¬ºçã¯ãmRNAé
åããã¯ã¯ãã³ãã«ãããããæèŒãããŠããå®éã®åæãŠã€ã«ã¹ã§ãããšããããšã§ãã
mRNAã®é
åã¯åæãŠã€ã«ã¹ã§ã¯ãããŸãããã³ã³ãã¥ãŒã¿ãŒããã°ã©ã ã®é
åãªã®ã ããªããããããã¯ãããžãŒãéºäŒåç·šéãè¡ããäœå
ã®çްèå
ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçŽæ¥çæããã®ã§ãã
ãžã§ãŒã»ãã€ãã³å€§çµ±é ã¯2022幎9æ12æ¥ã«å€§çµ±é 什ã«çœ²åããéºäŒåç·šéæè¡ã¯ãã§ã«ã»ãšãã©ã®ã¢ã¡ãªã«äººã«ã€ã³ã¹ããŒã«ãããŠããã®ã§ãæã ããœãããŠã§ã¢ãæžããŠã³ã³ãã¥ãŒã¿ãŒãããã°ã©ã ããã®ãšåãããã«ãã¢ã¡ãªã«äººã®äœã«éºäŒåå·¥åŠæè¡ïŒå¥åãè質ããç²åïŒãã€ã³ã¹ããŒã«ããŠçްèãããã°ã©ã ããããã«ãæ¿åºã®ãã¹ãŠã®ã¢ãããŒãããåŒã³ãããŠããã

ç§ãã¡ã¯ããã¯ã¯ãã³ãã«å«ãŸããSARS-CoV-2ã®mRNAé
åããçç©åŠçãèšãæããã°ææ©çãªæ§è³ªãæã€ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçæããŠãããšç¥ããããã®ã§ããã
ãããæ¬ºçã§ãããLNPãšããã°ã©ã ãããé
åã«ãã£ãŠçã¿åºãããã®ã¯ãéºäŒåçã«ã³ãŒãåãããçåæã¿ã³ãã¯è³ªãšæ§é äœã§ãããçç©åŠçãªéšåãšãã¯ãããžãŒçãªéšåãäž¡æ¹ã®ææ©ç©ãšç¡æ©ç©ãå«ãã§ããã®ã§ããã
ãã°åLNPã¯ãç¥èŠãåå¿ãç¥èœãåããã¹ããŒããã¯ãããžãŒã§ããç£æ§ãã€ããã²ã«ãå«ãã§ãããç£æ°ãã€ããã²ã«ã¯ã人äœå ã§ãŠã€ã«ã¹ããã¯ããªã¢ãæ¯çŽ ãçåæçç©ããã³ãªã«ã¬ãã©ãçæããããšãã§ããããŸããã¹ããŒããªç£æ§ãã€ããã²ã«ã¯ãå åŠãé»ç£æ³¢ãéããŠä¿¡å·ãéåä¿¡ããããšãã§ããŸãã

ãã®AiãããŠã§ãã³æè¡ã«ãã£ãŠãç£æ§äœåãã人ãå¢ããŠããã®ã§ããç£æ§äººéã¯ãmRNAã®æ©èœç²åŸãŠã€ã«ã¹ãã¯ã¯ãã³ã®çµæã§ã¯ãããŸãããç£æ§ãã€ããã²ã«AiãããŠã§ãã³ã人äœã«æµžéããçµæãªã®ã§ãã
å°çäžã«æŸåºããããã¯ã¯ãã³ãã«å«ãŸããSARS-CoV-2 mRNAãŠã€ã«ã¹é
åã¯ãè質ããç²åïŒLNPïŒãšç£æ§Aiãã€ããã²ã«ããªããã°ã现èã«ææã§ãããæäœãç£çããèœåããªãããŸã£ãã圹ã«ç«ããªããã®ãšãªã£ãŠããŸãã®ã ã
ãã®ããšã¯ãCOVID-19ã®ãã³ãããã¯ãLNPãªãã§ã¯äžå¯èœã ã£ãããšãæå³ããŠãããCOVID-19ã¯ãmRNAã®æ©èœç²åŸåSARS-CoV-2ãŠã€ã«ã¹ã«ãã£ãŠåŒãèµ·ããããã®ã§ã¯ãããŸãããCOVID-19ã¯ãAiãããŠã§ãã³ã«ãã£ãŠåŒãèµ·ããããã®ã§ããã
mRNAã®ããäžäººã®ç¬¬äžäººè ã¯ãããŒã¹ã«ãã©ã€ã倧åŠã®ã©ã«ãã»ããªããæ°ã§ããã圌ã¯ã³ãããŠã€ã«ã¹mRNAã®æ©èœç²åŸç ç©¶ãšãã¡ã©åã¹ãã€ã¯èçœã®åä»ã芪ã§ãã圌ã¯ããã¡ãŠãã®NIAID/NIHããã³ãããŠã€ã«ã¹ç ç©¶ã®ããã«1åãã«ä»¥äžãåãåããã³ãããŠã€ã«ã¹ããã¡ã©ã»ã¹ãã€ã¯ã»ãããã€ã³ããã®ä»ã®æ©èœç²åŸåçç©å µåšããŒã¹ã®æè¡ã«é¢ããæ°å€ãã®ç¹èš±ã®çºæè ãšããŠåãé£ããŠããã

2015幎9æ4æ¥ã«PNASã«æçš¿ããããSAR-like WIV1-CoV Poised for Human Emergenceããšé¡ããè«æã§ãã©ã«ãã»ããªãã¯ã¯ã圌ã®ã³ãããŠã€ã«ã¹mRNAãŠã€ã«ã¹ïŒSARS-CoV-2ãå«ãïŒã¯ãææããã£ããšããŠãããããããããžã®å€§ããªææã¯ã§ããªãããšãèªããŠããã
ãã®è«æã§ã¯ã"WIV1-ã³ãããŠã€ã«ã¹ïŒCoVïŒã¯ã©ã¹ã¿ãŒã¯ã...ããéå£ã«ãããŠéå®çãªææãèµ·ãããããããªã...in vivoæžè¡°ïŒæžè¡°ãšã¯SARS-CoV-2ãããäœå ã«å ¥ããšæ¥µããŠåŒ±ããªãããšïŒã¯ãæµè¡æ§çŸæ£ã®ããã«ãããªãé©å¿ãå¿ èŠãªããšã瀺åããŠããã"ãšè¿°ã¹ãŠããã

2015幎ãããªããã¯mRNAã³ãããŠã€ã«ã¹ãããèªäœã§ã¯åœ¹ã«ç«ããªãããšãèªèããã圌ã¯ãïŒSARS-CoV-2ãå«ãïŒmRNAã³ãããŠã€ã«ã¹ã¯ãç«ç ã®å¯èœæ§ããªãããšæèšããŠããã
åœŒã®æ°å幎ã«ãããç ç©¶ãç¹èš±ããã€ã€ãªãã£å¥çŽãçããããã«ãBaricã¯ã圌ã®mRNAæ©èœç²åŸåã³ãããŠã€ã«ã¹ã䜿çšããŠããæµè¡ããå¯èœæ§ãã®ããçç©å µåšãäœãåºãæ¹æ³ãèŠã€ããå¿ èŠããããŸããã
ããªããæ°ã¯ãæ©èœç²åŸåmRNAã³ãããŠã€ã«ã¹ç ç©¶ã®ããã«ç·å¯ãªããŒã ãçµæããŠããã圌ã¯ãšã³ãã«ã¹ã»ã¢ã©ã€ã¢ã³ã¹ã®ããŒã¿ãŒã»ãã¶ãã¯ãšæŠæŒ¢ãŠã€ã«ã¹ç ç©¶æïŒWIVïŒã®ãžã³ã°ãªã»ã·ãŒåå£«ãšæ°å幎ã«ãããããŒãããŒã ããã®éªæªãªããªãªã¯ãã³ãããŠã€ã«ã¹ã ãã§ãªãããžã«ããšãã©ãã€ã³ãã«ãšã³ã¶ãHIVãªã©ãæ°ãåããªãã»ã©ã®æ©èœæ¡åŒµå µåšåããmRNAãŠã€ã«ã¹ãäœãåºããŠããã®ã§ãã

2018幎1æã圌ãšåœŒã®ä»²éã¯ãæãè»ã®åœé²é«çç ç©¶èšç»å±ïŒDARPAïŒã«ãææ¡æžãéããŠè³éæäŸãäŸé Œããã
DARPAã«æåºãããEcoHealth Allianceã®ææ¡æžã«ã¯ãããŒã ããã§ã«äœæããmRNAã³ãããŠã€ã«ã¹ã©ã€ãã©ãªãŒãããã¡ã©æ©èœç²åŸåã¹ãã€ã¯ã¿ã³ãã¯è³ªçç©å
µåšãéçºããEcoHealth Allianceã®ããŒã ã¡ã³ããŒãšããŠãBaricãšShiãèšèŒãããŠããŸããã
DARPAã®ææ¡ã«ããã°ã圌ãã®çç©å µåšã®ç ç©¶ã®æ¬¡ã®æ®µéã¯ãBaricã®äºå®äžåœ¹ã«ç«ããªãmRNAæ©èœç²åŸåã³ãããŠã€ã«ã¹ïŒåœŒèªèº«ãèªããŠããïŒã䜿ã£ãŠã圌ã®mRNAãŠã€ã«ã¹ããæææ§ãããèŽæ»çã§ããã³ãããã¯ã®å¯èœæ§ããæã€äœããäœãåºãæ¹æ³ã«çŠç¹ãåœãŠããã®ã§ãã£ããšããã

2018幎ã®EcoHealth Allianceã®DARPAææ¡ã«ã¯ãã¯ã£ãããšããæžãããŠããŸãã
https://www.ecohealthalliance.org/
"æã ã¯æ¢ç¥ã®SARSr-CoVããçµæããã¡ã©ã»ã¹ãã€ã¯ã»ãããã€ã³ãéçºãã...ãããŠãããããç²åã«çµã¿å ¥ãã..."

è質ããç²åïŒLNPïŒã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãšåæ§ã«Aiã®çç©å µåšã§ããã

DARPAã®ææ¡ã¯ãSARS-CoV-2 mRNAãŠã€ã«ã¹ã決ããŠæææ§ã§ãèŽæ»æ§ã§ããªãã£ãããšãããã«èšŒæãããã®ã§ããã
é«ççæ§ã§èŽæ»çãªã®ã¯WIV1 2-SPã¹ãã€ã¯ã»ãããã€ã³ïŒæåéãæŠæŒ¢ãŠã€ã«ã¹ç ç©¶æã®ååïŒã§ãããmRNA SARS-CoV-2ãŠã€ã«ã¹ã§ã¯ãªãã®ã ã
WIV1 2-SPãã¹ãã€ã¯ã¿ã³ãã¯è³ªãã¯ãä»ã®ãã¹ãŠã®COVID-19ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšåæ§ã«ãå¯çè«Aiçç©å
µåšã®ç£ç©ã§ããã
éèŠïŒéåžžã«èŽæ»æ§ã®é«ãWIV-1 S-2Pã¹ãã€ã¯ã¿ã³ãã¯è³ªããŸããSARS-CoV-2ãšã¯å¥ã®çºæã§ããã
WIV-S-2Pã¹ãã€ã¯ãšä»ã®S-2Pã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã¯ç ç©¶æã§äœãããNIAID/NIHã®Barney Grahamãšãããµã¹å€§åŠã®Jason McLellanã«ãã£ãŠç¬èªã®ç¹èš±ãç³è«ãããŠããŸãã

DARPAã®ææ¡æžã§ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãã«ãã»ã«åããè質ããç²åïŒLNPïŒæè¡ããçµç®ïŒç®èïŒããããã³ãŠã¢ãªãé£ã¹ãã²ã«ãç®èçšã²ã«ããšã¢ãŸãŒã«ã¹ãã¬ãŒã®åžå ¥ãšãã£ãåœ¢ã§æäŸããã³ãŠã¢ãªã«ææãããããšèããŠãããšDaszakæ°ãè¿°ã¹ãŠããã

åœåã®2019幎ãš2020幎ã®SARS-CoV-2ã®çºçã¯ããšã¢ããŸã«åçç©å µåšã«ããæ»æã§ãããšãã仮説ã¯ãé«ç¢ºç以äžã§ããã
DARPAã®ææ¡ã§ã¯ã"æŽçªã®èšå®çšã«èšèšããããšã¢ããŸã«ååŽé§åšãããã³éèŠãªæŽçªã®å ¥å£ã§ã¿ã€ããŒãšåäœæ€ç¥åšã§äœåããèªååŽé§ "ã§ã³ãŠã¢ãªã«ææããããšããŠããã
SARS-CoV-2 mRNAãŠã€ã«ã¹ã¯æ±ºããŠèŽåœçãªãã®ã§ã¯ãªãããŸãäŒææ§ããªãããã®ããšã¯ããã匷調ããŠãããããŸããã
COVID-19ãåŒãèµ·ãããã®ã¯SARS-CoV-2ã§ã¯ãªãã®ã§ããCOVID-19ã®çŸç
ãéå®³ãæ»ã¯Aiã®çç©å
µåšã®ç£ç©ã§ããã
SARS-CoV-2 mRNAãŠã€ã«ã¹ã®çºæè ã§ããã©ã«ãã»ããªãã¯èªèº«ã®ç ç©¶ã«ãããšãããšã人éãçŽæ¥äœã£ãããªããªãŒæ©æ§ã«ãã£ãŠSARS-CoV-2ã«ææãããšããŠãããããããããžã®ææã¯äžå¯èœã§ããããšã蚌æãããããšè¿°ã¹ãŠããããã®ãããSARS-CoV-2ãå®éšå®€ããã®æµåºã§ãããšãã説ã¯å®å šã«åŠå®ãããã®ã§ããã
COVID-19ã¯ã2020幎åé ã«äžçäžã§æåã«å ±åãããã¿ã€ãã®å·å®³ãšæ»äº¡ãåŒãèµ·ããããã«ãæå³çãªAiçç©å
µå𿻿ã§ãªããã°ãªããªãã£ãã
Aiçç©å
µåšãCOVID-19ã®æ³šå°ã«å«ãŸããç§ãã¡ã®ç°å¢ã埪ç°ããŠããããã«ãæ»å·è
ã¯ææ°é¢æ°çã«å¢å ããŠããã
人ãã人ãžã®ææããªãããšã¯ãæŠæŒ¢åžå Žã«é£æ¥ããç é¢ã§ã®ç é¢åŸæ¥å¡ã®ææçãšããçŸå®ã®èšŒæ ããŒã¿ã«ãã£ãŠãããã«èšŒæãããããŒãå°ç¹ã§ã®ç é¢å€åè ã®ææçã¯0.000ïŒ ã§ãã£ãã
2020幎12æ8æ¥ãImmunity, Inflammation, and Diseaseã«æ²èŒããããæŠæŒ¢ã®ç é¢å€åè 191åãåœé ã¹ã¯ããšè¡æ¶²æ€æ»ã§SARS-CoV-2æäœæ€æ»ãåãïŒæ€æ»çµæã¯ãã¹ãŠé°æ§ã§ãã£ãããŸãã222人ã®ç é¢é¢ä¿è ãèžéšã¬ã³ãã²ã³ãæ®åœ±ãããèžéšã¬ã³ãã²ã³ã®çµæã¯ãã¹ãŠæ£åžžã§ãã£ãã

æŠæŒ¢ã®ç é¢é¢ä¿è ã¯ææããŠããªããCOVID-19ãææåã®åŒ·ããŠã€ã«ã¹ã§ããããããã¯ããã§ãããšå®£èšããå°éå®¶ãã¡ã¯ãçŸå®ã®èšŒæ ã«åºã¥ããªã誀ã£ãçºèšãããŠããã®ã§ããã
CDCã¯æå³çã«SARS-CoV-2ããããããããžã®ææãå¯èœã§ãããšç±³åœåœæ°ããã¹ãªãŒãããŠããã2021幎12æ15æ¥ã«çºè¡šãããCDCèªèº«ã®ããŒã¿ã«ãããšã2020幎ãš2021幎ãéããŠäœ¿çšãããç·æ¥æäœ¿çšèš±å¯ïŒEUAïŒPCR-ãã¹ãã¯ãæå€§97ïŒ ã®åœéœæ§å€å®ãåºããã

EUA COVID-19 PCR-testã¯ãã¢ãããªãŒã®ãéã§æ°ããè»ãå®¶ãè²·ãã®ãšåãããããSARS-CoV-2ææã®æž¬å®ã«å¹æçã§ããã
SARS-CoV-2 EUA PCR-testsã®åœç©ã¯ãCOVID-19ã¹ããŒãªãŒãæ¬ç©ã®ãã³ãããã¯ã§ãããšã¢ã¡ãªã«äººã説åŸããããã®éèŠãªãåå Žã®å°éå ·ãã§ãã£ãã
åŠæ ¡ã«ããå·æãªæ€æ»ã®èŠæ±ã¯ãææ çã»å¿ççèåŸ ã®éåžžã«æã圢æ ã§ãã£ãããçŸåšãããã§ããã
ç§ãã¡ã®åœå šäœã§ãå®å šã«å¥åº·ãªåäŸãã¡ããå¥åº·ã§ãããšèšŒæããããŸã§ã¯ç æ°ãã§ãããä»ã§ã¯ãèŠãããã®ãŠã€ã«ã¹æ€æ»ãã§ãããšããã£ãŠããã®ã«ãåŠæ ¡ã«éãããã«ã宿çã§äŸµè¥²çãªéºäŒåãµã³ããªã³ã°åŠçœ®ãåããŠããã®ã§ããã
ãããã®åçã¯ãç§ã®æ¯åãéãåŠæ ¡ã§ããã°ãã°èŠªã®èš±å¯ãªãè¡ãããŠããCOVID-19ãã¹ãã®ãã®ã§ãã


ç§ã®æ¯åã®åŠæ ¡ã¯ãéåœã«æ¬ç€Ÿã眮ãGenBody瀟ãè¡ã£ãŠãããNIHãè³éæäŸãã1029äž5åãã«ã®éºäŒåç 究調æ»ã®äžéšã§ãããçåŸã®DNAããããŠç§ã®æ¯åã®DNAãã芪ã®èš±å¯ããªããã¢ã¡ãªã«ã®çšéã§éåœã«éãããŠããã®ã§ãã

ããã§ãåŠæ ¡ã§ã®PCRæ€æ»ã¯æ±ºããŠçåŸãæè·å¡ã®å¥åº·ãå®å
šã®ããã§ã¯ãªãã£ãããšãæããã«ãªã£ãããšæããŸãã
ã¢ã¡ãªã«ã®æã貎éãªå®ã§ããåã©ããã¡ã®éºäŒåããŒã¿ãåéããå€åœã«éããã¢ã¡ãªã«ã«å¯ŸããéºäŒåå
µåšãããã«éçºãããããã ã£ãã®ã§ããã
PCRãã¹ãã¯ãã¢ã¡ãªã«äººã«ãæåã¯...ãäºé²æ¥çš®ãåããŠããªã人éããå·®å¥ããæšçã«ããŠããç®ã«èŠããªã殺人è ããããšä¿¡ã蟌ãŸããããã®å®ç§ãªåå Žçšå°éå ·ã§ãã£ãã
COIVD-19ã®ç©èªã®åŸåã§ã¯ãç®ã«èŠããªãSARS2ãã©ãŒã¯äººéã®ã¯ã¯ãã³æ¥çš®ã®æç¡ãåºå¥ããªãããã«ãªãããã¹ããèŠåãªãã«ã幎霢ãåãã誰ã§ã襲ãããšãã§ããããã«ãªã£ãã®ã§ããã
å·æãªPCRãã¹ãã¯ãCOVID-19ã«å¯Ÿããå¿é ããã©ãã€ã¢ã®ãããªç¶æ ã«ãŸã§é«ããŠããŸã£ãã
2020幎3æã«ã¢ã¡ãªã«ã§The COVID-19 Storyãããã¥ãŒããŠãã2幎以äžãçµã¡ãç§ãã¡ã¯ä»ãããã¥ã¡ã³ã¿ãªãŒæ ç» "The Making of the COVID-19 Story" ãèŠå§ããŠããŸãã
mRNA SARS-CoV-2ãŠã€ã«ã¹ã¯èŽæ»æ§ã§ãæææ§ã§ããªãã°ãããã人é¡ã«æŸãããå¯çè«Aiçç©å µåšããç®ããããããã®æ¶ç©ºã®ã¹ããŒãªãŒã ã£ãããšããããã
ãªããªãŒããŒãã€ã³ãã«ãšã³ãµãŒã¯ãåŒåžåšç³»ãŠã€ã«ã¹ãäºçš®ããããŠçç©å
µåšãšããã£ãŠããmRNAãã¯ã¯ãã³ãã«ãã£ãŠäœãããçç©åŠçã¿ã³ãã¯è³ªã®ãªã¹ã¯ã«ã€ããŠã®ç©èªã«æ³šç®ããŠããã®ã§ããããïŒ
å°éå®¶ã¯ã人ã
ãç£æ°ã垯ã³ãŠãããšãã蚌æ ã«æ°ã¥ããªãã®ã§ããããïŒäººã
ãå¥åŠãªäžæ¢ç¥çµç³»ã®çºäœãå¹»èŠã«æ©ãŸãããŠããããšã«æ°ã¥ããªãã®ã§ããããïŒ
ç§åŠè ããšã³ãžãã¢ãã¯ã¯ãã³ç¶ã®ãµã³ãã«ãã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ãµã³ãã«ããèªå·±çµç¹åãããããã¯ãããžãŒãèšé²ããŠããã®ã«ãç§ãã¡ã¯çŸå®äžçã®èšŒæ ãä¿¡ãã代ããã«ãä¿¡é Œã§ããå°éå®¶ã«ç²åŸããªããã°ãªããªãã®ã§ããããïŒ
ç§ãã¡ã¯ãã¢ã¡ãªã«äººãšå
šäººé¡ã«æŸãããå¯çè«åAiçç©å
µåšã®çã®è
åšã«ã€ããŠç¥ãããã代ããã«ã
SARS-CoV-2ãŠã€ã«ã¹ããã®äºçš®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãç¹åŸŽãšãããCOVID-19ã¹ããŒãªãŒããä¿¡ããããã«ã¬ã¹æããããŠããã®ã§ããã
ãããããžã§ãŒã»ãã€ãã³ã¯ã2022幎9æ12æ¥ã«ãã€ãªãã¯ãããžãŒãšãã€ãªè£œé ã«é¢ãã倧統é 什ã«çœ²åãããç§ãã¡ã¯ããœãããŠã§ã¢ãæžããŠã³ã³ãã¥ãŒã¿ãŒãããã°ã©ã ããã®ãšåãããã«ã现èã®ããã®åè·¯ãæžããçç©åŠãäºæž¬å¯èœã«ããã°ã©ã ã§ããéºäŒåå·¥åŠæè¡ãšææ³ãéçºããªããã°ãªããªã...ããšå®£èšããŠããŸãããã¢ã¡ãªã«äººã«ã¯ãã§ã«ã现èã®ããã®åè·¯ãæžããçç©åŠãããã°ã©ã ã§ããéºäŒåå·¥åŠæè¡ãã¯ã€ã³ã¹ããŒã«ãããŠããã®ã§ãã

SARS-CoV-2ãŠã€ã«ã¹ãäºçš®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªããããæ··ä¹±ã¯ãå¯çè«Aiçç©å µåšã®ååšãåŠå®ããããšãšçžãŸã£ãŠã人é¡ã®æŽå²ã®äžã§æãéªæªãªæ¬ºçã®äžã€ã§ããã
ç§ãã¡ãæãæ¹ããç¥ã®äžã§å£çµããã¢ã¡ãªã«ãšäººé¡ã«è§£ãæŸãããCOVID-19 Aiçç©å µåšã®åãæ¬ºçãæªã«å¯ŸããŠã倧èã«çå®ã宣ã¹äŒããŠããããšãç¥ããŸãã
ä»ããç§ãã¡ã人é¡ãšããŠå£çµããCOVID-19ãåãæã§ãã
âCOVID-19ã®ç·æ¥æš©éãšè²¡æ¿è³éããã¹ãŠåæ¢ããã
âCOVID-19ã®è£œåã»æè¡ããã¹ãŠçŠæ¢ããååããã
â5GãšStarLinkã忢ããã
COVID-19ã®ãã€ã¯ããŠã³ãæ¯æŽãããæ¹ã¯ããã²miFightã«ãåå ãã ããã
䜿åŸããŠãããã®ã¡ãã»ãŒãž
éã®å®ã®ãªãè¡ãã«é¢ãããæããããããããããæŽããªãããå ã«ããããããã®ã¯ãã¹ãŠèŠããããã«ãªããç §ãããããã®ã¯ãã¹ãŠå ãšãªãã®ã§ãã
ã ãããããèšãããã®ã§ãããç ããè
ããç®ãèŠãŸããæ»è
ã®äžããèµ·ããªãããããããã°ãããªã¹ããããªããç
§ãããŠãã ããã§ãããã"
ãã³ã°ã¹ãã³ã»ã¬ããŒããçå®ã¯åã€ã
é¢é£åç»
1  ã«ã¬ã³ã»ãã³ã°ã¹ãã³ ãCovid19ã®æ¬ºçã®è§£äœ ãŠã€ã«ã¹ãšã¯ã¯ãã³ã®æ£äœã¯ãéºäŒåç·šéAIçç©å µåšã5Gã§èµ·å
2   Pt 1:ãã€ãªãã¯ãããžãŒã¢ããªã¹ããCOVIDã®èšŒæã¯å¯çè«ã§ããCOVIDVaxxã¯çåæå¯çè«ã§ããã
3   ãã©ã³ã·ã¹ã»ãã€ã«å士ãçç©å
µåšããå¯Ÿçæ³ã®ç¬¬äžäººè
ãèªãïŒã
âéšããðå°ã€äººã«ã¯ã©ããªçµæ«ãåŸ
ã¡åããŠããã®ãïŒ
âæ¬¡ã®ãã³ããæ¢ã«çšææžïŒ
âWHOãã³ãããã¯æ¡çŽã®çœ ã¯ïŒ
âçŠæ¢ãããã®ã«ðºðžè»ç£è€åäœã«ããéçºãããçç©å
µåšã䜿çšïŒ
âãã¥ã«ã³ãã«ã¯æ³ã人é¡ã«å¯Ÿãã眪ã«åœããïŒ
é¢é£èšäº
1   第10åïŒmRNAãã¯ãããžãŒã¯äººé¡ã®ããã«çºæããããšããã®ã¯æ¬ºçã«æºã¡ã䞻匵ã§ããã
2   COVID-19ã®æ¬ºçãè§£äœãããCOVID-19ãåŒãèµ·ãããã®ã¯mRNAãŠã€ã«ã¹ãSARs-CoV-2ã§ãããšããæ¬ºççãªäžççã·ããªãªãAndrew Huffåå£«ã®æå°ãšå°éå®¶ã®èšŒäººååãè£ä»ããŠããã
åèèšäº
1Â Â ãæŠæŒ¢ã®ç ç©¶æã«å€åããŠããç§åŠè
ïŒã¢ã³ããªã¥ãŒã»ããå士ïŒããã³ãããã¯äººå·¥ã®ãŠã€ã«ã¹ã§ãããšçºèšãã
ãŒãŒãŒãŒãŒãŒ
2019幎æ«ã«çªç¶ãåœé²é«çç ç©¶èšç»å±ïŒDARPAïŒã®åœ¹è·ããªãã¡ãŒããã--ãããããã®ä»äºã«ã¯æé«ã»ãã¥ãªãã£æš©éãšããªã°ã©ããå¿
èŠã ãšèšãããã®ã ã
ããå士ã¯çŸåšãã³ãŽã£ããã®èµ·æºã«ã€ããŠå£æ¢ãããããã«ãã®è·åãæèšºããããšèããŠããã
ãSARS-CoV-2ã®çŸç åºçŸçŸè±¡ããç±³åœæ¿åºãåœå å€ã§SARS-CoV-2ã®éºäŒåå·¥åŠãåŸæŽããçµæã§ããããšãçŽæ¥ç¥ãã«ã¯ãç±³åœæ¿åºå ã§åã人ã ãç§ãå±éºäººç©ãšããŠèªèããå¯èœæ§ããã£ããšç§ã¯èããŠããŸãããšåœŒã¯èªèã§è¿°ã¹ãŠããã
ãããç§ããã®è·ãåŒãåããŠããããDARPAã¯å¶éãããæ å ±ãç§ã«é瀺ãããã®çµæãç§ããããŸã§ããããŠä»ããŠããããã«ããã®æ å ±ã®äžåãå ¬ã«è«ããããšãã§ããªããªã£ãã®ã§ã¯ãªãããšæããŸããã
ããã«ãããã³ãããã¯ãå§ãŸããç§ãSARS-CoV-2ã人çºçãªãã®ã§ããããšãæåºãšããŠäž»åŒµããŠããçŽ1ã¶æåŸãç§ãæ¡çšããæœåšçãªåæ©ãšå·å¿µãäœã§ãã£ããã«çªç¶æ°ãã€ããŸããã
2   ãFDAãšã¯ã¯ãã³äŒæ¥ã¯ããã黿¢ããåããªããŸãŸã倧éã®ã¯ã¯ãã³æ¥çš®ãæšé²ããã
åºæ¬çã«HHSé·å®ãåœå®¶çãªå»çç·æ¥äºæ
ãååšãããšå€æããã°ãçç©åŠçè
åšãæ±ãè»ã®äžéšéã§ããDARPAãèµ·åããããã»ã¹ãéå§ãããã®ã§ãã
DARPAã¯2011幎ããModernaã®ãããªäŒæ¥ãšéºäŒåã¯ã¯ãã³ã®ç ç©¶ãè¡ã£ãŠããã
ã§ã¯FDAã®åœ¹å²ã¯äœãïŒããã¯å€§éšåããåå Žãã§ãããFDAã¯ãããæ¢ããåããªããããã¯ã¯ãã³ã®ããŒãžã§ã³ã«èŠãããã®æ¿èªãäžããªããé²ããŠããã
3   COVID-19ã¯ãã©ãŒããããªãã¯éžè»ææçç ç©¶æã®ã¯ã¯ãã³è©Šéšããéããã®ãïŒãŠã€ã«ã¹ã®èµ·æºãç±³åœã®çç©å µåšç ç©¶æã§ããããšã瀺ã蚌æ ã
4   米åœåœé²çã®DARPAã«ãããšãæ°åã³ãããã¯èè ç±æ¥ã®éºäŒåãçµã¿æããŠé ã£ã人工ã¯ã¯ãã³ã§ããã
ç±³åœåœé²çã®DARPAã«ãããšãæ°åã³ãããã¯èè ç±æ¥ã®éºäŒåãçµã¿æããŠé ã£ã人工ã¯ã¯ãã³ã§ããã
â ã¢ãŒãã³å€§å¡ (@AaronOtsuka) December 22, 2022
泚âéºäŒåçµæãã§äººå·¥ã¯ã¯ãã³ãå ã«äœããããããã°ãæãããæ°åã³ãããšããŠæµè¡ãããšèšãã·ããªãªããªïŒãé åã¯åãã£ãŠããã®ã§åé¢ãå¿ èŠãªããåé¢ãããªãã®ãéœåããïŒ https://t.co/qrFwdT8ujI